Echinacea Clinical Trials Recruiting Now

Echinacea trials recruiting now

1 registration that name echinacea as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.

Trial Finder Read from ClinicalTrials.gov Oct 20, 2026 The Echinacea supplement page

Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.

RecruitingNCT07388615

The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children

Phase 2
Al-Azhar University
About 60 people
Starts Jan 18, 2026 (estimated)

In plain words A Phase 2 study of echinacea in people 5 to 12, run by Al-Azhar University. It plans to enroll about 60 people at 1 site, none in the US.

Who it lists and where

Who the trial lists, as registered

Lists people 5 to 12. Conditions: Cryptosporidium Infection.

Clinical diagnosis of Cryptosporidiosis Disease
Age from 5-12 years
Immunocompromised children
Not receiving any drugs causing immunosuppression

The exclusion criteria are on the listing.

What it tests, as registered

Echinacea Extract

Registered summary

This study aims to: 1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children. 2. To measure the changes in parasite count in stool samples after treatment with Immulant ®. 3. To assess the safety and tolerability of Immulant ® in children participating in the study.

Where, as registered

No US site; Egypt (1).